On October 12, 2021, Aimed Alliance submitted a comment to the Centers for Medicare & Medicaid Services (CMS) on its proposed rule that would revoke the November 27, 2020 Most Favored Nation (MFN) Model Rule. The MFN Model Rule would have placed price caps on 50 Medicare Part B prescription drugs. The price caps for these drugs would have been based on the lowest price that drug manufacturers receive in countries similar to the U.S. In our comment, we supported CMS revoking the MFN Model Rule and cautioned against the use of pricing models that impair patient access to innovative medications. Specifically, we cautioned against the use of international drug reference pricing, which can stifle innovation, result in less investment in research and development of new drugs, and impair patient access to medications. We also cautioned against the use of domestic reference pricing, which often uses QALYs to assess the value of medications and can result in patient discrimination based on their age and health status. Our full comment can be read here.